Objective
Tumors are characterized by a disorganized vasculature, leading to profound levels of hypoxia. Normalizing the blood vessel formation (angiogenesis) in tumors has therefore become an attractive therapeutic strategy, leading to the development of approved drugs that inhibit major angiogenic pathways. Resistance however restricts the success of these anti-angiogenic drugs in some patients. There is thus a great clinical need for readily accessible markers that serve as reliably predictive biomarkers of anti-angiogenic therapies. However, all markers discovered to date have a limited predictive power. In the ERC Consolidator Grant CHAMELEON, we discovered how tumor hypoxia causes DNA hypermethylation and how changes in DNA methylation underlie resistance to anti-angiogenesis. Here, we propose to validate how methylation patterns detectable in plasma circulating free DNA from a prospective collection of patients with metastatic colorectal cancer can be used to predict an early response to anti-angiogenic therapies by using our in-house developed cfDNA co-methylation test, referred as the ‘INITIATOR’ test. If successful, we anticipate that this project will overcome many of the issues that are currently associated with anti-angiogenic drugs: cfDNA is readily accessible and can be serially sampled during treatment or follow-up, cfDNA also mirrors the entire tumor and not just the biopsied site, while the epigenetic changes detectable in cfDNA may be a dynamic representation of the tumor in response to treatment.
Call for proposal
ERC-2019-PoC
See other projects for this call
Funding Scheme
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotHost institution
9052 Zwijnaarde - Gent
Belgium
Beneficiaries (1)
9052 Zwijnaarde - Gent
